Further evidence of anxiety- and depression-like behavior for total genetic ablation of cannabinoid receptor type 1

Soriano, Delia; Brusco, Alicia; Caltana, Laura

doi:10.1016/j.bbr.2020.113007

Cited by 12 publications

(6 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are reports proving beneficial effects of cannabis in treating depression in patients, who did not respond to standard pharmacological methods [ 53 ]. Attenuation of signaling in the endocannabinoid system correlates with psychiatric disorders development, such as anxiety, depression and schizophrenia, which has been repeatedly proven in animal studies and clinical trials [ 54 ]. The complex pharmacology of several cannabinoids is related to the modulation of release of neurotransmitters engaged in depression development in the serotonergic [ 55 ], glutamatergic [ 56 ] and endocannabinoid pathways, together with alterations on molecular and cellular levels [ 57 , 58 ].…”

Section: Discussionmentioning

confidence: 99%

Cannabinoids—Perspectives for Individual Treatment in Selected Patients: Analysis of the Case Series

et al. 2022

View full text Add to dashboard Cite

Cannabinoids can be successfully used in the treatment of many symptoms and diseases; however, most often they are not the drugs of first choice. They can be added to the primary therapy, which can improve its effectiveness, or be introduced as the basic treatment when the conventional methods have failed. Small clinical trials and case reports prove the benefits of applying medicinal cannabis in various indications; however, clinical trials in larger groups of patients are scarce and often controversial. Due to limited scientific evidence, it is essential to conduct further experimental trials. Understanding the role of endocannabinoids, as well as the composition of cannabis containing both phytocannabinoids and terpenes plays an important role in their clinical use. The clinical effects of cannabinoids depend, among other things, on the activity of the endocannabinoid system, the proportion of phytocannabinoids, such as Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and the dosage used. The article discusses the role of phytocannabinoids and the potential of using them in different clinical cases in patients suffering from chronic pain, opioid dependence, depression and migraine, who did not respond to the conventional therapeutic methods. In each of the presented cases, the implementation of cannabinoids altered the course of the disease and resulted in symptom relief. Every decision to introduce cannabinoids to the treatment should be made individually with careful attention paid to details. Additionally, it is worth taking care of good clinical communication and education so that the implemented therapy is safe, effective and properly perceived by the patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Cannabinoids—Perspectives for Individual Treatment in Selected Patients: Analysis of the Case Series

et al. 2022

View full text Add to dashboard Cite

show abstract

“…47 , 48 This receptor is widely distributed in the central nervous system, with expression occurring mainly in areas closely related to emotion regulation such as the prefrontal cortex, hippocampus, amygdala, basal ganglia, striate nucleus, adrenergic ganglion cells of the mesencephalon, and cerebellum. 18 , 49 This receptor is also expressed in GABAergic, glutamatergic, serotoninergic, and noradrenergic axon terminals. Therefore, its activation inhibits neurotransmitter release by temporarily or permanently modulating synaptic transmission.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, CB1R activation produces anxiolytic and antidepressant effects as well as potentiating the effects of classic antidepressants. 18 Endocannabinoid signalling is a part of an endogenous anxiolytic neuromodulating system; therefore, inhibiting fatty acid amide hydrolase activity is a potentially promising therapeutic approach to reduce symptoms related to anxiety, 12,15,20 suggesting that the ECS plays an important role in modulating anxiety and depression. 47,48 A recent 2021 study by Laczkovics et al 31 presented the case of a 17-year-old male patient with severe depression, social phobia, narcissistic personality disorder, and multiple substance abuse.…”

Section: Discussionmentioning

confidence: 99%

“…The main function of the ECS is to maintain homeostasis in the organism. 18 Some of the anxiolytic effects of CBD occur when it interacts with components of the ECS, which are intimately related to emotions because of their distribution in the 'emotional' or limbic system, where they regulate synaptic neurotransmission. 19 However, its effects are not limited to the ECS: this cannabinoid has demonstrated that it is able to interact with a great variety of receptors in the human body (many of which are related to anxiety modulation) as well as with endogenous and exogenous molecules.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

Rios¹,

Ruiz²,

Dumani³

2022

DIC

View full text Add to dashboard Cite

Anxiety-related disorders are one of the most common mental health issues worldwide. Mexico has reported an increase in the prevalence of these ailments secondary to the confinement derived from the COVID-19 pandemic. Given the limitations of commonly used treatments for these disorders, a need arises to develop new pharmacological treatments for these patients. This paper has the primary objective of evaluating the efficacy and safety of cannabidiol isolate in drug compounding used as a personalized treatment in patients with anxiety disorders through the presentation of four clinical cases.

show abstract

“…They are based on their ability to modulate several signalling pathways involved in the development of depression, including serotoninergic, noradrenergic, glutamatergic and endocannabinoid systems [83][84][85]. The homeostasis of the endocannabinoid system seems to be of key importance as the attenuation of its signalling is correlated with many psychiatric disorders, such as anxiety, depression and schizophrenia [86]. Therefore, the endocannabinoid system has been put forward as a promising new pharmaceutical target for treatment-resistant depression disorders [87].…”

Section: Depression and Mood Disordersmentioning

confidence: 99%